News
Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...
As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...
Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...
Novo Nordisk cut 2025 sales forecast citing competition from compounded versions of its Wegovy weight-loss drug. Invezz takes ...
My doctor said patients have told him they were able to stop drinking and even quit cocaine use while taking Wegovy.
Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...
Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...
The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...
The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback